Ajanta Pharma has announced that the US Food and Drug Administration (FDA) concluded an inspection at its manufacturing facility in Paithan, Maharashtra. The inspection, which took place from 13th April to 21st April 2026, resulted in the issuance of a Form-483 with five observations.
The company has stated that it will respond to the US FDA within the stipulated timeline, addressing the observations noted during the inspection. A Form-483 is issued when investigators observe any conditions that may violate the Food Drug and Cosmetic (FD&C) Act and related Acts. The observations do not represent a final FDA determination regarding compliance.
Ajanta Pharma, a prominent player in the pharmaceutical industry, is committed to maintaining high standards of quality and compliance in its manufacturing processes. The company is expected to take corrective actions to address the observations and ensure compliance with FDA regulations.
The inspection at the Paithan facility underscores the ongoing regulatory scrutiny faced by pharmaceutical manufacturers, particularly those with operations in multiple countries. Ajanta Pharma‘s management is likely to prioritise addressing these observations to avoid any potential impact on its operations or product approvals in the US market.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).